Results 211 to 220 of about 119,936 (354)

Determining oncology nurses' awareness of cardio-oncology in Türkiye: A descriptive study. [PDF]

open access: yesAsia Pac J Oncol Nurs
Kalkan Uğurlu Y   +3 more
europepmc   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia   +6 more
wiley   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe   +4 more
wiley   +1 more source

Montelukast attenuates diclofenac sodium-induced cardiotoxicity in male rats via targeting Wnt/β-catenin pathway. [PDF]

open access: yesSci Rep
Alsanea S   +8 more
europepmc   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena   +5 more
wiley   +1 more source

Delivery of nano‐formulated drugs to solid tumours is selectively increased by co‐application of the vascular disrupting agent CA4P

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and purpose Nano‐formulated chemotherapeutics prolong systemic availability of drugs and can reduce systemic toxicity, but their accumulation in solid tumours is often limited and unpredictable. Broadly applicable strategies to selectively enhance tumour delivery are lacking.
Annabel Kitowski   +13 more
wiley   +1 more source

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

open access: yesCancer Science, EarlyView.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou   +15 more
wiley   +1 more source

An update on the landscape of collagen bioactive fragments

open access: yesThe FEBS Journal, EarlyView.
The remodeling of the extracellular matrix releases collagen bioactive fragments, which exert molecular functions and regulate numerous biological processes via several signaling pathways. Here, we summarize the latest findings describing the roles of major bioactive fragments from collagens I, IV, VI, and XVIII in various physiological and ...
Sylvie Ricard‐Blum, Julie Fradette
wiley   +1 more source

Enhancing Breast Cancer Survivorship Care: The Role of Nurses in Post‐Treatment Follow‐Up—A Scoping Review

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aim To examine the role of nurses in providing post‐treatment follow‐up care to breast cancer survivors, and to assess the impact of this care on survivors' satisfaction. Methods Scoping review. Data Sources An electronic literature search from PubMed and CINAHL databases was conducted, covering the period from 2013 to November 2023.
Judith Gálvez‐Sánchez   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy